{"schema_version":"secwatch.filing_event.v1","accession":"0001847367-25-000026","form_type":"8-K","ticker":"ALMS","cik":"0001847367","company_name":"ALUMIS INC.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.125647+00:00","generated_at":"2026-05-21T10:20:18.319313+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Alumis Q1 net loss $99M, revenue $17.4M; merger with ACELYRIN on track for Q2 2025 close","bullets":["Net loss of $99M in Q1 2025 vs $49.8M in Q1 2024; revenue of $17.4M from Kaken license fee.","Cash and marketable securities $208.7M as of March 31, 2025; combined pro forma cash $737M with ACELYRIN.","Merger with ACELYRIN approved by Alumis stockholders; exchange ratio 0.4814; expected close in Q2 2025.","ESK-001 Phase 3 psoriasis topline data expected early Q1 2026; SLE Phase 2b data in 2026.","R&D expenses $96.6M (up 130% YoY) driven by Phase 3 ONWARD program acceleration."],"urls":{"canonical":"https://secwatch.observer/filing/0001847367-25-000026","json":"https://secwatch.observer/filing/0001847367-25-000026.json","markdown":"https://secwatch.observer/filing/0001847367-25-000026.md","text":"https://secwatch.observer/filing/0001847367-25-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000026/0001847367-25-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000026/alms-20250514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T10:20:18.319313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}